Earlier in December 2025, Recursion Pharmaceuticals reported positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, showing rapid and durable reductions in polyp burden ...

The simulation hypothesis—the idea that our universe might be an artificial construct running on some advanced alien computer ...

In 2025, Anthropic will grow from $1 billion to $9 billion in ARR (annual recurring revenue). OpenAI, meanwhile, will go from ...

The staff at the Center for a New American Security dove into researching some of the most pressing and hard-hitting national ...